18 -6 (38) 2021 — Ergashev B.B., Akhmedova N.Sh. — INTERACTION OF TREATMENT OF ONCOPATHOLOGY AND CARDIOVASCULAR DISEASES

INTERACTION OF TREATMENT OF ONCOPATHOLOGY AND CARDIOVASCULAR DISEASES

Ergashev B.B., Bukhara State Medical Institute

Akhmedova N.Sh. Bukhara State Medical Institute

Resume

This article study the relationship between cardiovascular disease and cancer risk, identifies the mechanisms associated with cardiotoxicity, and describes the screening and follow-up of patients undergoing cancer treatment. It also describes the screening and monitoring of patients undergoing cancer treatment. Effective prevention and treatment strategies are presented to reduce the incidence of cardiotoxicity in those receiving chemotherapy drugs or radiation.

Key words: cardiovascular disease, chemotherapy, complication, oncopathology, risk factors

First page

99

Last page

103

For citation: Ergashev B.B., Akhmedova N.Sh. INTERACTION OF TREATMENT OF ONCOPATHOLOGY AND CARDIOVASCULAR DISEASES //New Day in Medicine 6(38)2021 99-103 https://cutt.ly/IYuqpFm

LIST OF REFERENCES:

1. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines / The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) // Eur. Heart. J. – 2016. – Vol. 21, № 37 (36). – Р. 2768–2801.
2. Abdel-Wahab N, Shah M, Suarez-Almazor M E. Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports. PLOS ONE. 2016; 11(7):e0160221.
3. Armenian Saro H et.all. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2017; 35:893–911.
4. Azrad Maria, Demark-Wahnefried Wendy. The association between adiposity and breast cancer recurrence and survival: A review of the recent literature. Current nutrition reports. 2014; 3:9–15.
5. Bail Jennifer, Meneses Karen, Demark-Wahnefried Wendy. Nutritional Status and Diet in Cancer Prevention. Seminars in oncology nursing. 2016; 32:206–214.
6. Bambs Claudia, Kip Kevin E, Dinga Andrea, Mulukutla Suresh R, Aiyer Aryan N, Reis Steven E. Low prevalence of “ideal cardiovascular health” in a community-based population: the heart strategies concentrating on risk evaluation (Heart SCORE) study. Circulation. 2011; 123:850–857.
7. Baskar Rajamanickam, Lee Kuo Ann, Yeo Richard, Yeoh Kheng-Wei. Cancer and radiation therapy: current advances and future directions. International journal of medical sciences. 2012; 9:193–199.
8. Begg Adrian C, Stewart Fiona A, Vens Conchita. Strategies to improve radiotherapy with targeted drugs. Nature reviews. Cancer. 2011; 11:239–253.
9. Cardinale Daniela, Biasillo Gina, Salvatici Michela, Sandri Maria Teresa, Cipolla Carlo Maria. Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. Expert review of molecular diagnostics. 2017; 17:245–256.
10. Chang Hui-Ming, Moudgil Rohit, Scarabelli Tiziano, Okwuosa Tochukwu M, Yeh Edward T H. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. Journal of the American College of Cardiology. 2017; 70:2536–2551.
11. Chen C L. Cardiovascular prevention in the cancer survivor. Current Atherosclerosis Reports. 2015;17(6):1–10.
12. Coviello J S, Knobf M T. Screening and management of cardiovascular risk factors in cancer survivors. In: Fadol A, editor. Cardiac complications of cancer therapy. Pittsburg, PA: Oncology Nursing Society; 2013. pp. 267–296.
13. Herrmann Joerg, Lerman Amir, Sandhu Nicole P, Villarraga Hector R, Mulvagh Sharon L, Kohli Manish. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clinic proceedings. 2014; 89:1287–1306.
14. Higgins Angela Y, O’Halloran Thomas D, Chang James D. Chemotherapy-induced cardiomyopathy. Heart failure reviews. 2015; 20:721–730.